Roth Capital Reiterates Buy On Curis Following IND Filing, Keeps $10 Price Target
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated coverage with a “Buy” rating on Curis Inc. (CRIS), and a price target of $10.00 a share following today’s news that CRIS’ partner Roche (RHHBY) filed an IND to initiate a Phase II study of Erivedge in idiopathic pulmonary fibrosis (IPF).
Pantginis comments: “We see this IND as a positive for CRIS as it represents Erivedge’s first expansion into non-oncology indications. We believe that the drug could have applications in a variety of non-oncology as well as oncology indications based on its mechanism of targeting the Hedgehog signaling pathway. The Hedgehog pathway is implicated in idiopathic pulmonary fibrosis, which is a debilitating lung disease often occurring in smokers that is characterized by the scaring of lung tissue leading to progressive shortness of breath. It is usually fatal.
With CUDC-427 back on track, Erivedge generating royalties in oncology, and this expansion of the drug into the non-oncology space, we believe CRIS valuation remains attractive”.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Joseph Pantginis currently has a one-year average return of -6.1% and a 33% success rate. Pantginis has a 6.9% average loss recommending CRIS, and he is ranked #3050 out of 3123 analysts.